Cigna: Pandemic Led to Fewer New Scripts, Better Adherence

In its 2020 Drug Trend Report, Cigna Corp. division Evernorth said total drug costs rose 4% for its commercial plans, including both utilization and unit costs. The COVID-19 pandemic led to an across-the-board decline in the percentage of new medication users as well as improved adherence among people taking medications for chronic conditions. Among the top 15 therapy classes ranked by per-member per-year spend for the commercial plans, inflammatory conditions remained the top of the list, at $241.34 PMPY average spending, followed by diabetes at $145.24.

SOURCE: Evernorth. Visit https://www.evernorth.com/drug-trend-report.

Jinghong Chen

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

bills-and-pills
May 19

Various Components Play Important Role in Companies’ Definition, Demonstration of Drugs’ Value

Read More
abdominal-pain-patient-with-a-doctor
May 19

FDA’s Rinvoq Approval Brings Another Ulcerative Colitis Option

Read More
pills-and-dollars
May 19

Study: With High Prices, Rebate Revenue Is Growing for PBMs

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today